Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia
Status:
Completed
Trial end date:
2018-05-02
Target enrollment:
Participant gender:
Summary
This trial will determine the Pharmacokinetics, safety and tolerability of single-dose
Aripiprazole administered intramuscularly in adults with schizophrenia
Phase:
Phase 1
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.